Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

AIDS

Volumn 14, Issue 4, 2000, Pages 383-386

  Soriano, Vincent ^a,b   Dona, Carmen ^a   Rodríguez Rosado, Rafael ^a   Barreiro, Pablo ^a   González Lahoz, Juan ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

Antiretroviral therapy; Immune restoration; Opportunistic infections; Prophylaxis

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CD4 ANTIGEN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; KETOCONAZOLE; PENTAMIDINE; PYRIMETHAMINE; SULFADIAZINE;

ADULT; ARTICLE; CANDIDIASIS; CHEMOPROPHYLAXIS; COST OF ILLNESS; CYTOMEGALOVIRUS INFECTION; FEMALE; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROPHYLAXIS; RETINITIS; TOXOPLASMOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; VIRAL LOAD;

EID: 0034026096     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200003100-00011     Document Type: Article

References (33)

1. 1. Centers for Disease Control and Prevention. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with HIV. AIDS 1997, 46(RR-12):1-46.
2. 2. Saah A, Hoover D, Peng Y, et al. Predictors for failure of PCP prophylaxis. MACS. JAMA 1995, 273:1197-1202.
3. 3. Murphy R, Lavelle J, Allan J, et al. Aerosol pentamidine prophylaxis following PCP in AIDS patients: results of a blinded dose-comparison study using an ultrasonic nebulizer. Am J Med 1991, 90:418-426.
4. 4. Podzamczer D, Miró JM, Bolao F, et al. Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group. Ann Intern Med 1995, 123: 175-180.
5. 5. Katlama C, De Wit S, O'Doherty E, van Glabeke M, Clumeck N: Pyrimethamine-clindamycin versus pyrimethamine-sulfadine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS, Clin Infect Dis 1996, 22:268-275.
6. 6. Septowitz K. Effect of HAART on natural history of AIDS-related opportunistic disorders. Lancet 1998, 351:228-230.
7. 7. Martin D, Kuppermann B, Wolitz R, Palestine A, Li H, Robinson C. Oral ganciclovir for patients with CMV retinitis treated with a ganciclovir implant. N Engl J Med 1999, 340:1063-1070.
8. 8. Spector S. Prediction, prevention and treatment of cytomegalovirus disease in persons with AIDS. AIDS Reviews 1999, 1: 15-21.
9. 9. Walmsley S, Khorasheh S, Singer J, Djurdjev O. A randomized trial of NAC for prevention of cothrimoxazole hypersensitivity reactions in PCP prophylaxis (CTN 057). J AIDS Hum Retrovirol 1998, 19:498-505.
10. 10. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced HIV infection. N Engl J Med 1998, 338:853-860.
11. 11. Hogg R, O'Shaughnessy M, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997, 349:1294.
12. 12. Jahnke N, Montessori V, Hogg R, Anis A, O'Shaughnessy M, Montaner J. Impact of triple drug therapy on morbidity, mortality and cost. AIDS Reviews 1999, 1:57-60.
13. 13. Autran B, Carcelain G, Li T, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
14. 14. Li T, Tubiana T, Katlama C, Calvez V, Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral load reduction after HAART in advanced HIV-1 disease. Lancet 1998, 351:1682-1686.
15. 15. Carcelain G, Li T, Autran B. Immune reconstitution under HAART. AIDS Reviews 1999, 1:51-56.
16. 16. Connors M, Kovacs J, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3: 533-540.
17. 17. Douek D, McFarland R, Keiser P, et al. Changes in thymic function with age and during the treatment of HIV. Nature 1998, 396:690-695.
18. 18. Schneider M, Borleffs J, Stolk R, et al. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with HAART. Lancet 1999, 353:201-203.
19. 19. Furrer H, Egger M, Opravil M, et al. Discontinuation of primary prophylaxis against PCP in HIV-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999, 340:1301-1306.
20. 20. Furrer H, Jacobson M, Reiss P, Telenti A. Discontinuation of prophylaxis against opportunistic infections in HIV-infected persons receiving potent combination antiretroviral therapy. AIDS Reviews 1999, 1:179-188.
21. 21. Tural C, Romeu J, Sirera G, et al. Long lasting remission of cytomegalovirus retinitis without maintenance therapy in HIV-infected patients. J Infect Dis 1998, 177:1080-1083.
22. 22. McDonald J, Torriani F, Morse L, et al. Lack of reactivation of CMV retinitis after stopping maintenance therapy in AIDS patients with sustained elevation of T cells in response to HAART. J Infect Dis 1998, 177:1182-1187.
23. 23. Aberg J, Yajko D, Jacobson M. Eradication of disseminated Mycobacterium avium complex after twelve months anti-mycobacterial therapy and response to HAART. J Infect Dis 1998, 177:1182-1187.
24. 24. Gripshover B, Valdez H, Salata R, et al. Withdrawal of fluconazole suppressive therapy for thrush in patients responding to combination antiviral therapy including protease inhibitors. AIDS 1999, 12:2513-2514.
25. 25. Powderly W, Landay A, Lederman M. Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA 1998, 280:72-77.
26. 26. Jacobson M, Zegans M, Paven P, et al. Cytomegalovirus retinitis after initiation of HAART. Lancet 1997, 349:1443-1445.
27. 27. Casado JL, Pérez-Elias MJ, Martí-Belda P, et al. Improved outcome of CMV retinitis in AIDS patients after introduction of protease inhibitors. J AIDS Hum Retrovirol 1998, 19:130-134.
28. 28. Race E, Adelson-Mitty J, Kriegel G, et al. Focal mycobacterial lymphadenitis following initiation of protease inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998, 351: 252-255.
29. 29. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997, 349:996-997.
30. 30. Rodriguez-Rosado R, Soriano V, Dona C, et al. Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antiviral Therapy 1998, 3:229-231.
31. 31. Lyles R, Chu C, Mellors J, et al. Prognostic value of plasma HIV-RNA in the natural history of PCP, CMV and MAC. AIDS 1999, 13:341-349.
32. 32. Williams P, Currier J, Swindells S. Joint effects of HIV-RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections. AIDS 1999, 13:1035-1044.
33. 33. Castilla J, Gutiérrez A, Guerra L, et al. Pulmonary tuberculosis and extrapulmonary tuberculosis at AIDS diagnosis in Spain: epidemiological differences and implications for control. AIDS 1997, 11:1583-1588.